ImmunityBio, Inc. (IBRX): A Bull Case Theory 

We came across a bullish thesis on ImmunityBio, Inc. on HalfBakedInnovations’s Substack by Biotech Distilled. In this article, we will summarize the bulls’ thesis on IBRX. ImmunityBio, Inc.'s share was trading at $3.9500 as of January 15th.

ImmunityBio, Inc., a commercial stage biotechnology company, develops next-generation therapies that bolster the natural immune systems to defeat cancers and infectious diseases. IBRX has achieved a major inflection point with the Saudi Food and Drug Authority granting accelerated approval for ANKTIVA in metastatic non-small cell...